CASE REPORT article
Front. Oncol.
Sec. Gastrointestinal Cancers: Hepato Pancreatic Biliary Cancers
Volume 15 - 2025 | doi: 10.3389/fonc.2025.1546217
Surufatinib related nephrotic syndrome in a pancreatic neuroendocrine tumor: a case report and review of literature
Provisionally accepted- 1Second Affiliated Hospital, Zhejiang Chinese Medical University, Hangzhou, China
- 2Zhejiang Cancer Hospital, University of Chinese Academy of Sciences, Hangzhou, Zhejiang, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Pancreatic neuroendocrine tumors (pNETs) are rare, heterogenous neoplasms originating from pancreatic neuroendocrine cells, which regulate hormone secretion and metabolic homeostasis.Pancreatic neuroendocrine tumors (pNETs) are rare malignancies originating from the pancreas. Surgery is the primary method of control and potential cure for pNETs and targeted therapies have also been investigated for low-grade inoperable or distant metastatic pNETs. Surufatinib, an oral angioimmuno kinase inhibitor, is approved for treating inoperable or late-stage, low-grade (G1 and G2), well-differentiated pNETs and extrapancreatic neuroendocrine tumors. This study describes a case of nephrotic syndrome in a middle-aged woman with pNETs. This patient showed nephrotic syndrome after surufatinib treatment 3 months and renal pathology suggested IgA nephropathy with moderate podocyte injury. However, the nephrotic syndrome was relieved after 2 weeks of discontinuation of surufatinib. After resuming treatment with low-dose surufatinib for 2 weeks, the random proteinuria quantification was increased and the proteinuria turned negative after discontinuation of surufatinib again. It provides a reference for surufatinib related nephrotic syndrome in patients with pNETs and the potential mechanism between surufatinib and podocyte injury in IgA nephropathy needs to be investigated.
Keywords: Pancreatic neuroendocrine tumors, IgA nephropathy, Nephrotic Syndrome, surufatinib, podocyte
Received: 16 Dec 2024; Accepted: 28 Apr 2025.
Copyright: © 2025 Shi, Lin, Xiang, Bao and Yang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Chengqian Shi, Second Affiliated Hospital, Zhejiang Chinese Medical University, Hangzhou, China
Jie Yang, Second Affiliated Hospital, Zhejiang Chinese Medical University, Hangzhou, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.